Amgen 2001 Annual Report Download - page 22
Download and view the complete annual report
Please find page 22 of the 2001 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.-
1 -
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
-
10
-
11
-
12 -
13 -
14 -
15 -
16 -
17 -
18 -
19 -
20 -
21 -
22 -
23 -
24 -
25 -
26 -
27 -
28 -
29 -
30 -
31 -
32 -
33
-
34
-
35
-
36
-
37
-
38
-
39
-
40
-
41
-
42
-
43
-
44
-
45
-
46
-
47
-
48
-
49
-
50
-
51
-
52
-
53
-
54
 |
 |
In our business, most research
projects fail. If you’re right 30%
of the time, that’s a stupendous
batting average. But to get there,
you must start with an effective,
disciplined, and seamlessly inte-
grated product development
process. And at the heart of that
process is good decision-making.
To achieve the ambitious
goals we’ve set for ourselves
in each of our therapeutic
areas, we must be willing
to conscript good ideas
wherever they originate.
That includes a strategy
of licensing promising
therapeutic candidates
from other organizations.
We’re at a rare and
exciting inflection point
for Amgen. As advanced
therapeutics prove their
worth in the health care
marketplace, we have an
opportunity to build an
organization with a
research capacity unlike
any other in the industry.
Roger Perlmutter, MD, PhD Executive Vice President, Research and Development
Science Worth Pursuing
“R&D is the life blood of any therapeutics endeavor, but
it’s much more than that at Amgen. It goes to the very core
of our identity.”
20